|This biographical article relies too much on references to primary sources. (November 2009)|
|Brian J. Druker|
|Institutions||Howard Hughes Medical Institute, Oregon Health & Science University|
|Alma mater||University of California, San Diego|
|Notable awards||Robert Koch Prize (2005)
Keio Medical Science Prize (2007)
Meyenburg Prize (2009)
Lasker Clinical Award (2009)
Japan Prize (2012)
Dickson Prize (2012)
Albany Medical Center Prize (2013)
Brian J. Druker (born 1955) is a physician-scientist at the Oregon Health & Science University. He is the director of OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, and professor of medicine. In 2009 he won the Lasker Clinical Award and the Meyenburg Cancer Research Prize for his influential work in the development of STI571, commonly known as Gleevec, for the treatment of chronic myeloid leukemia (CML).
Dr. Druker earned both his BS in chemistry and MD from the University of California, San Diego. He completed internship and residency in internal medicine at Barnes Hospital, Washington University School of Medicine in St. Louis from 1981 to 1984. He was a fellow in medical oncology at Dana-Farber Cancer Institute, Harvard Medical School from 1984 to 1987.
Dr. Druker is an investigator of Howard Hughes Medical Institute (HHMI), and was elected to the Institute of Medicine of National Academies in 2003, the American Association of Physician in 2006, and the National Academy of Sciences in 2007. In addition to the Lasker and Meyenburg awards, he was presented the Hope Funds Award of Excellence for Clinical Research in 2009.